Clinical significance of UNC5B expression in colorectal cancer

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 209-216

  Okazaki, Satoshi ^a   Ishikawa, Toshiaki ^a   Iida, Satoru ^a   Ishiguro, Megumi ^a   Kobayashi, Hirotoshi ^a   Higuchi, Tetsuro ^a   Enomoto, Masayuki ^a   Mogushi, Kaoru ^a   Mizushima, Hiroshi ^a   Tanaka, Hiroshi ^a   Uetake, Hiroyuki ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Methylation; UNC5B

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; MESSENGER RNA; PROTEIN UNC5B; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; COLORECTAL CARCINOMA; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE PRODUCT; GENE SILENCING; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

AGED; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HCT116 CELLS; HT29 CELLS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84455163052     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1201     Document Type: Article

References (37)

1. Grady WM and Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135: 1079-1099, 2008.
2. Jones PA and Laird PW: Cancer epigenetics comes of age. Nat Genet 21: 163-167, 1999. (Pubitemid 29070360)
3. Esteller M: Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 8: 286-298, 2007.
4. Wong JJ, Hawkins NJ and Ward RL: Colorectal cancer: a model for epigenetic tumorigenesis. Gut 56: 140-148, 2007. (Pubitemid 46044900)
5. Rashid A and Issa JP: CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 127: 1578-1588, 2004. (Pubitemid 39457781)
6. Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer 4: 988-993, 2004.
7. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB and Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96: 8681-8686, 1999. (Pubitemid 29354851)
8. Issa JP: The epigenetics of colorectal cancer. Ann N Y Acad Sci 910: 140-153, 2000.
9. van Rijnsoever M, Grieu F, Elsaleh H, Joseph D and Iacopetta B: Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51: 797-802, 2002. (Pubitemid 35408598)
10. Herman JG, Umar A, Polyak K, et al.: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95: 6870-6875, 1998. (Pubitemid 28278073)
11. K ane MF, Loda M, Gaida GM, et al.: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57: 808-811, 1997.
12. Veigl ML, Kasturi L, Olechnowicz J, et al.: Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 95: 8698-8702, 1998. (Pubitemid 28350551)
13. Miyamoto K and Ushijima T: Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 35: 293-301, 2005. (Pubitemid 41444276)
14. Worm J and Guldberg P: DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. J Oral Pathol Med 31: 443-449, 2002.
15. Morita S, Iida S, Kato K, Takagi Y, Uetake H and Sugihara K: The synergistic effect of 5-aza-2′-deoxycytidine and 5-fluorouracil on drug-resistant tumors. Oncology 71: 437-445, 2006.
16. Ishiguro M, Iida S, Uetake H, et al.: Effect of combined therapy with low-dose 5-aza-2′-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann Surg Oncol 14: 1752-1762, 2007. (Pubitemid 46790993)
17. O gino S and Goel A: Molecular classification and correlates in colorectal cancer. J Mol Diagn 10: 13-27, 2008.
18. Thiebault K, Mazelin L, Pays L, et al.: The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proc Natl Acad Sci USA 100: 4173-4178, 2003. (Pubitemid 36418176)
19. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
20. Bernet A and Mehlen P: Dependence receptors: when apoptosis controls tumor progression. Bull Cancer 94: E12-E17, 2007.
21. Mehlen P and Llambi F: Role of netrin-1 and netrin-1 dependence receptors in colorectal cancers. Br J Cancer 93: 1-6, 2005. (Pubitemid 41076245)
22. Mehlen P and Fearon ER: Role of the dependence receptor DCC in colorectal cancer pathogenesis. J Clin Oncol 22: 3420-3428, 2004. (Pubitemid 41103701)
23. Rodrigues S, De Wever O, Bruyneel E, Rooney RJ and Gespach C: Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis. Oncogene 26: 5615-5625, 2007. (Pubitemid 47267839)
24. Bernet A, Mazelin L, Coissieux MM, et al.: Inactivation of the UNC5C Netrin-1 receptor is associated with tumor progression in colorectal malignancies. Gastroenterology 133: 1840-1848, 2007. (Pubitemid 350186160)
25. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
26. Fearon ER, Cho KR, Nigro JM, et al.: Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247: 49-56, 1990.
27. Mehlen P and Puisieux A: Metastasis: a question of life or death. Nat Rev Cancer 6: 449-458, 2006.
28. Macdonald JS and Astrow AB: Adjuvant therapy of colon cancer. Semin Oncol 28: 30-40, 2001. (Pubitemid 32172408)
29. O 'Connell MJ, Laurie JA, Kahn M, et al.: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16: 295-300, 1998.
30. Arkenau HT, Rettig K and Porschen R: Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Colorectal Dis 20: 258-261, 2005. (Pubitemid 40553005)
31. Moriguchi K, Yamashita S, Tsujino Y, Tatematsu M and Ushijima T: Larger numbers of silenced genes in cancer cell lines with increased de novo methylation of scattered CpG sites. Cancer Lett 249: 178-187, 2007. (Pubitemid 46452925)
32. Tanikawa C, Matsuda K, Fukuda S, Nakamura Y and Arakawa H: p53RDL1 regulates p53-dependent apoptosis. Nat Cell Biol 5: 216-223, 2003. (Pubitemid 36322248)
33. Arakawa H: Netrin-1 and its receptors in tumorigenesis. Nat Rev Cancer 4: 978-987, 2004.
34. Arakawa H: p53, apoptosis and axon-guidance molecules. Cell Death Differ 12: 1057-1065, 2005.
35. Suzuki H, Tokino T, Shinomura Y, Imai K and Toyota M: DNA methylation and cancer pathways in gastrointestinal tumors. Pharmacogenomics 9: 1917-1928, 2008.
36. K antarjian H, Issa JP, Rosenfeld CS, et al.: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106: 1794-1803, 2006.
37. Cashen AF, Schiller GJ, O'Donnell MR and DiPersio JF: Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 28: 556-561, 2010.